Perla Pucci, Liam C Lee, Miaojun Han, Jamie D Matthews, Leila Jahangiri, Michaela Schlederer, Eleanor Manners, Annabel Sorby-Adams, Joshua Kaggie, Ricky M Trigg, Christopher Steel, Lucy Hare, Emily R James, Nina Prokoph, Stephen P Ducray, Olaf Merkel, Firkret Rifatbegovic, Ji Luo, Sabine Taschner-Mandl, Lukas Kenner, G A Amos Burke, Suzanne D Turner
Targeting Anaplastic lymphoma kinase (ALK) is a promising therapeutic strategy for aberrant ALK-expressing malignancies including neuroblastoma, but resistance to ALK tyrosine kinase inhibitors (ALK TKI) is a distinct possibility necessitating drug combination therapeutic approaches. Using high-throughput, genome-wide CRISPR-Cas9 knockout screens, we identify miR-1304-5p loss as a desensitizer to ALK TKIs in aberrant ALK-expressing neuroblastoma; inhibition of miR-1304-5p decreases, while mimics of this miRNA increase the sensitivity of neuroblastoma cells to ALK TKIs...
April 23, 2024: Nature Communications